These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2019 related items for PubMed ID: 25306226

  • 1. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [Abstract] [Full Text] [Related]

  • 2. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M, Antonarakis ES, Luo J.
    Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
    [Abstract] [Full Text] [Related]

  • 3. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
    Graham L, Schweizer MT.
    Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
    [Abstract] [Full Text] [Related]

  • 4. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C, Antonarakis ES, Luo J, Yeh S, Chang C.
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [Abstract] [Full Text] [Related]

  • 5. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R, Lin W, Lin C, Li L, Sun Y, Chang C.
    Cancer Lett; 2016 Aug 28; 379(1):154-60. PubMed ID: 27233475
    [Abstract] [Full Text] [Related]

  • 6. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I, Day TK, Tilley WD, Selth LA.
    Endocr Relat Cancer; 2016 Dec 28; 23(12):T179-T197. PubMed ID: 27799360
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ, Milowsky MI, Whang YE.
    Clin Pharmacol Ther; 2015 Dec 28; 98(6):582-9. PubMed ID: 26331358
    [Abstract] [Full Text] [Related]

  • 11. Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance.
    Rezaei S, Mahjoubin Tehran M, Sahebkar A, Jalili A, Aghaee-Bakhtiari SH.
    J Cell Physiol; 2020 Apr 28; 235(4):3222-3234. PubMed ID: 31599460
    [Abstract] [Full Text] [Related]

  • 12. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
    Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B, Hager JH.
    Cancer Discov; 2013 Sep 28; 3(9):1020-9. PubMed ID: 23779130
    [Abstract] [Full Text] [Related]

  • 13. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
    Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV.
    Cancer Treat Rev; 2015 Dec 28; 41(10):884-92. PubMed ID: 26342718
    [Abstract] [Full Text] [Related]

  • 14. Androgen receptor aberrations in the era of abiraterone and enzalutamide.
    Jentzmik F, Azoitei A, Zengerling F, Damjanoski I, Cronauer MV.
    World J Urol; 2016 Mar 28; 34(3):297-303. PubMed ID: 26100946
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
    Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.
    Oncogene; 2014 May 29; 33(22):2815-25. PubMed ID: 23752196
    [Abstract] [Full Text] [Related]

  • 17. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
    Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.
    Eur Urol; 2018 May 29; 73(5):715-723. PubMed ID: 29258679
    [Abstract] [Full Text] [Related]

  • 18. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
    Lim AC, Attard G.
    Curr Drug Targets; 2013 Apr 29; 14(4):408-19. PubMed ID: 23565754
    [Abstract] [Full Text] [Related]

  • 19. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.
    Eur Urol; 2017 Apr 29; 71(4):680-687. PubMed ID: 27733296
    [Abstract] [Full Text] [Related]

  • 20. Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.
    Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP.
    Cancer Res; 2018 Nov 15; 78(22):6354-6362. PubMed ID: 30242112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 101.